Symbol | Exchange | Currency |
|---|
Xenetic Biosciences XBIO +126%, Medigus MDGS+35%, ImmunoPrecise Antibodies (IPA) -36%, Adverum Biotechnologies ADVM -23%
Adverum Biotechnologies Inc (NASDAQ: ADVM) has decided to drop the development of ADVM-022 intravitreal (IVT) injection gene therapy in diabetic macular edema (DME) after...
Adverum Biotechnologies (ADVM) said that it no longer plans to develop ADVM-022 for the treatment of diabetic macular edema ((DME)) after a dose-limiting toxicity at the high dose...
Los Angeles, USA , March 09, 2021 (GLOBE NEWSWIRE) -- Age-related Macular Degeneration Pipeline Analysis of 70+ Key Companies and 70+ Key Therapeutic Products DelveInsight...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,735.80 | 2,765.00 | 2,706.70 | +97.8 | +3.71% | 3.46M | NASDAQ | |||
| 372.90 | 377.54 | 367.00 | +5.09 | +1.38% | 15.18M | NASDAQ | |||
| 155.75 | 162.91 | 153.55 | -11.85 | -7.07% | 193.00K | NYSE | |||
| 88.68 | 90.00 | 84.67 | -2.64 | -2.89% | 1.69M | NASDAQ | |||
| 195.01 | 196.40 | 189.76 | +8.94 | +4.80% | 26.55M | NYSE | |||
| 53.19 | 53.92 | 52.94 | +0.01 | +0.02% | 18.00M | NASDAQ | |||
| 195.06 | 196.46 | 189.95 | +2.98 | +1.55% | 14.41M | NASDAQ | |||
| 43.63 | 43.74 | 42.26 | +1.53 | +3.63% | 36.34M | NYSE | |||
| 300.86 | 302.39 | 296.98 | +0.38 | +0.13% | 3.62M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 61.07 | 61.55 | 60.43 | -0.09 | -0.15% | 643.91K | NYSE | |||
| 21.13 | 21.25 | 20.91 | +0.14 | +0.67% | 6.85M | NYSE | |||
| 38.80 | 39.55 | 36.08 | +0.79 | +2.08% | 60.44M | NYSE | |||
| 20.38 | 20.65 | 20.16 | +0.02 | +0.10% | 5.15M | NYSE | |||
| 13.06 | 13.25 | 12.91 | +0.11 | +0.85% | 1.62M | NYSE |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
